Association Between Female Genital Schistosomiasis and High-Risk Human Papillomavirus Among Women of Reproductive Age in Zambia: The Schista Study Authors: Olimpia Lamberti, Rhoda Ndubani, Jennifer Fitzpatrick, Emily Webb, Nkatya Kasese, Beatrice Nyondo, Barry Kosloff, Maina Cheeba, Philippe Mayaud, Morgan E Lemin, Pytsje T Hoekstra, Govert Van Dam, Paul Corstjens, Lisette Van Lieshout, Bonnie Webster, Helen Ayles, Isaiah Hansingo, Bodo Randrianasolo, Dingase Kuwemba, Bellington Vwalika, Paul Kamfwa, Kwame Shanaube, Helen Kelly, Amaya L Bustinduy Published: 2026 ABSTRACT AbstractBackgroundFemale genital schistosomiasis (FGS), a gynecological disease caused by Schistosoma haematobium egg deposition in the female genital tract, is prevalent in sub-Saharan Africa, the region with the highest cervical cancer burden globally. Persistent high-risk human papillomavirus (HR-HPV) infection is necessary for cervical cancer development. We determined the association between FGS and HR-HPV genotypes in Zambian women.MethodsSexually active women aged 15–50 years, not menstruating or pregnant, were recruited at home and provided 2 cervicovaginal self-swabs, urine sample, and HIV and Trichomonas vaginalis self-tests, and completed a questionnaire. In clinic, midwives collected cervicovaginal swabs and cervical images with point-of-care colposcopy (EVA System, MobileODT). Swabs were analyzed for 14 HR-HPV types (GeneXpert) and Schistosoma DNA (ITS-2 real-time polymerase chain reaction [qPCR]); urine was analyzed for Schistosoma ova by microscopy and circulating anodic antigen. Visual FGS was defined as colposcopic identification of specific genital lesions, and molecular FGS as Schistosoma-positive cervicovaginal qPCR.ResultsAmong 2532 women (median age, 28 [interquartile range, 22–36] years) recruited at home, 1694 (67%) completed clinic follow-up. Prevalence of visual FGS, molecular FGS, and HR-HPV was 35.2% (595/1691), 6.5% (165/2532), and 28.7% (690/2401), respectively. Molecular FGS was weakly associated with all HR-HPV (adjusted odds ratio [aOR], 1.3 [95% confidence interval {CI}, .9–1.9]). Women with molecular FGS were more likely to test positive for HR-HPV types 16/18/45 (aOR, 1.7 [95% CI, 1.0–2.8]). No association was observed between visual FGS and HR-HPV infection (95% CI, .7–1.1).ConclusionsThis is the first study to jointly screen for FGS and HR-HPV in Zambia, reporting an association between oncogenic HR-HPV types and molecular FGS. Female genital schistosomiasis (FGS) is a neglected gynecological disease estimated to affect 30–56 million women globally, mostly in sub-Saharan Africa [1, 2]. It is caused by Schistosoma haematobium egg deposition in the female genital tract, which induces an inflammatory response, the formation of granulomas, and epithelial damage presenting as characteristic cervicovaginal mucosal lesions [1, 2]. Untreated FGS is associated with sexual dysfunction and reproductive tract morbidity, including infertility, dyspareunia, and genital symptoms mimicking sexually transmitted infections (STIs) [2]. Despite its high burden, FGS remains underdiagnosed and overlooked in schistosomiasis and in sexual and reproductive health (SRH) programs [1, 2]. There are no guidelines for FGS screening, diagnosis, or treatment [2–4]. Conventional diagnosis involves colposcopy to collect cervicovaginal images, then analyzed by gynecologists and classified as suggestive of “visual FGS” if characteristic cervicovaginal mucosal findings (homogeneous sandy patches, grainy sandy patches, rubbery papules, or abnormal blood vessels) are observed [2–5]. This requires expensive equipment, advanced clinical infrastructure, and specialized training, often not available in S haematobium–endemic settings [2, 6]. In addition, concordance between expert reviewers is poor (Cohen κ = 0.16), highlighting the low specificity of visual FGS diagnosis [6]. Molecular testing using polymerase chain reaction (PCR) to detect S haematobium DNA in genital swabs (“molecular FGS”) offers a potentially scalable and specific diagnostic method [3, 7]. Genital samples can be self-collected at home, potentially increasing screening coverage [3, 7]. Zambia has the third-highest incidence and mortality rates of cervical cancer globally, with 65.5 new cases and 43.4 cancer deaths per 100 000 women annually [8–11]. Persistent infection with 1 of the 12 high-risk human papillomavirus (HR-HPV) types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59) is a necessary cause of cervical cancer [12]. HPV-16 and -18 account for 70% of all cervical cancer cases [12, 13]. HR-HPV is primarily sexually transmitted, and risk factors include early sexual debut, multiple lifetime sexual partners, high parity, hormonal contraceptive use, and STI coinfection [14]. Women with human immunodeficiency virus (HIV-1) have 2-fold increased risk of acquiring HR-HPV [15], and 6-fold increased risk of cervical cancer, compared to women without HIV [16, 17]. The chronic genital inflammation caused by S haematobium eggs may facilitate HR-HPV acquisition, persistence, and progression to cervical precancer, yet this requires further investigation [2, 18]. The World Health Organization (WHO) announced a global call to eliminate cervical cancer by 2030, setting targets to vaccinate 90% of girls against HPV by age 15, screen 70% of eligible women with high-performance tests, and treat 90% of women with cervical cancer [19]. Zambia launched its national HPV vaccination program in 2019 and is transitioning from visual inspection with acetic acid to HPV DNA–based screening, due to its higher sensitivity and specificity to detect cervical precancer [20]. HPV DNA testing can be performed on provider- or self-collected samples, with comparable sensitivity and specificity between the 2 methods [20–22]. Molecular testing for FGS could be integrated into the cervical cancer screening programs and delivered at home for multipathogen community-based screening [7, 8]. Understanding the epidemiological overlap between FGS and HR-HPV is essential to inform integrated screening strategies [7]. Previous studies exploring the association of FGS and HPV in sub-Saharan Africa showed mixed results [2, 18]. A study in Zimbabwe among 236 women (aged 15–49 years) showed an association between composite FGS diagnosis by visual and molecular methods and HR-HPV infection (age-adjusted odds ratio [OR], 1.9 [95% confidence interval {CI}, 1.1–3.6], P = .032) [23]. Another South African study (N = 933) found strong association between visual FGS and any HR-HPV infections (detected by GP5+/6+ HPV PCR test) (adjusted OR [aOR], 1.71 [95% CI, 1.14–2.56], P = .010) [24]. In contrast, a study in Madagascar (N = 302) found no association between visual FGS and infection with any HPV (high- and low-risk genotypes) (OR, 1.0 [95% CI, .82–1.2]) [25]. A study in Tanzania found no differences in HR-HPV rates between women with and without Schistosoma infection, detected by circulating anodic antigen (CAA), an indirect measure that does not indicate genital involvement [26]. To date, no study has evaluated the association between FGS diagnosed using both visual and molecular diagnostic methods and individual HR-HPV genotypes. This study aims to determine the risk factors for HR-HPV and the association of HR-HPV prevalence and FGS diagnosed by visual and molecular diagnostic methods, in an ongoing longitudinal cohort in Zambia (Zipime-Weka-Schista study). MATERIALS AND METHODS Study Design and Participants The Zipime-Weka-Schista (Do-self-testing sister!) study is a 4-year longitudinal cohort study evaluating the performance of multipathogen self-sampling for genital infections among women in Zambia [27]. This analysis uses baseline data collected between January 2022 and April 2023, across 3 sites (Livingstone, Sikoshwe, and Chanyanya). Women aged 15–50 years, who were nonpregnant, nonmenstruating, sexually active, and resident for at least a year in the study sites, were eligible. Participants were randomly selected through community-based random sampling and enrolled at home by Schista community workers (SCWs) [27]. Sample Collection During home visits, participants provided written informed consent, completed a questionnaire, and self-collected 2 cervicovaginal swabs and a urine specimen [27]. One swab was stored in PrimeStore molecular transport media (MTM; donated by Longhorn Vaccines and Diagnostics LLC, Bethesda, MD, USA) for Schistosoma DNA detection (Supplementary Text 1) [27]. The second swab was stored in PrimeStore MTM (80% of baseline samples) or in ThinPrep Cytopreserve solution (Supplementary Text 1). Urine was tested on the same day on-site for S haematobium egg-patent infection by urinary microscopy (Supplementary Text 2). A 2-mL urine sample was shipped to Leiden University Medical Centre, The Netherlands, for Schistosoma CAA detection using the up-converting reporter particle lateral flow CAA test (UCAAhT417 format; CAA levels >0.6 pg/mL were considered positive) (Supplementary Text 3) [28]. Participants were offered HIV (OraQuick HIV Self-Test) and Trichomonas vaginalis self-tests (OSOM Trichomonas Rapid Test). Results were read by the SCW and immediately shared with the participant. HIV-positive self-tests were confirmed on-site using a point-of-care diagnostic test (Determine) [27]. Participants with positive HIV or T vaginalis results were referred for treatment and care. Following the home visit, participants were invited for the clinic follow-up where a midwife collected 2 cervicovaginal swabs, a cervicovaginal lavage (CVL), and cervicovaginal images with a point-of-care colposcope (EVA MobileODT, Tel Aviv, Israel). One cervicovaginal swab was stored in PrimeStore MTM and the second in Cytopreserve. The CVL specimen was stored at −20°C for future analysis (Supplementary Text 1). Visual FGS Colposcopic cervicovaginal images were independently evaluated remotely by 2 gynecologists (B. R. and D. K.). In case of disagreement, a third reviewer (I. H.) independently analyzed the images. Participants were classified as visual FGS positive if at least 2 reviewers independently identified at least 1 of the 4 typical FGS lesion types, and negative if no lesions were observed [5]. Molecular FGS Cervicovaginal swabs stored in PrimeStore MTM were processed at Zambart central laboratory (Lusaka, Zambia) for Schistosoma DNA detection using internal transcribed spacer 2 (ITS-2) by real-time PCR (ITS qPCR) (Supplementary Text 4). Total nucleic acid extraction (PrimeXtract Longhorn Vaccines and Diagnostics) was performed as per manufacturer's instructions, using a simplified silica-based spin column extraction process. qPCR was performed as previously reported and results were reported as cycle threshold (Ct) values and considered positive if any Ct value was observed and negative if no Ct value was observed [3, 29]. Women were classified as molecular FGS positive if either self- or provider-collected cervicovaginal swab tested positive. Women with evidence of schistosomiasis, molecular FGS, and/or visual FGS received 40 mg/kg praziquantel single dose [30]. HR-HPV Detection Self-collected cervicovaginal swabs stored in either PrimeStore MTM or in ThinPrep Cytopreserve were tested for HR-HPV detection using a multiplex real-time PCR assay (GeneXpert HPV, Cepheid, USA), which simultaneously detects 14 HR-HPV types (HPV types 16, 18, 45, 31, 33, 35, 52, 58, 51, 59, 39, 56, 66, and 68), grouped into 3 channels: HPV-16; HPV-18 or -45 (or both); and any other HR-HPV types. DNA extraction for samples stored in PrimeStore MTM was performed using a modified PrimeXtract spin column protocol (Supplementary Text 5). For GeneXpert HPV analysis, 50 µL of the extracted DNA was diluted in 1 mL of normal saline and loaded into the GeneXpert cartridge, following the standard assay protocol. A sample adequacy control and a probe check control was also provided in the cartridge (Supplementary Text 5). If a test result on the self-collected swab was invalid, HR-HPV testing was done using the healthcare provider-collected swab (Supplementary Text 6). HR-HPV Definitions Participants were classified as HR-HPV positive if positive for at least 1 of 14 HR-HPV types; HPV-16/18/45 positive if positive for HPV type 16, and/or HPV type 18 and/or 45 channels; and HPV-16 positive if only HPV type 16 channel was positive (Supplementary Figure 1). Samples were classified as invalid if both the home-based self-collected swab and clinic-based swab were invalid (Supplementary Text 6). HR-HPV–positive women were referred to a gynecologist for colposcopy and a 2-quadrant cervical biopsy according to age and HIV status [27]. All women with cervical precancer were referred for management as per national guidelines [20]. Statistical Analyses Data were entered on electronic devices using Open Data Kit and analyzed using Stata version 17.0 software (StataCorp, USA). Primary outcomes were detection of any HR-HPV, HPV-16/18/45, and HPV-16 only. Descriptive statistics summarized participants’ characteristics, stratified by outcomes. Univariable logistic regression analyses were used to estimate crude ORs (cORs) and 95% CIs for the associations between HR-HPV and potential risk factors. Potential risk factors were informed by the published literature. Multivariable logistic regression models were used to estimate aORs for the associations between HR-HPV and factors associated with HR-HPV in univariable analysis. Covariates with missing data were excluded. Multicollinearity was assessed between variables in the final models. Ethical Considerations The study was approved by the University of Zambia Biomedical Research Ethics Committee (UNZABREC) (reference: 1858-2021), the Zambian National Health Research Authority (Reference: 00012/24/09/2021), and the London School of Hygiene and Tropical Medicine (LSHTM) (reference: 25258). RESULTS At baseline, 2532 women (median age, 28 years [interquartile range {IQR}, 22–36 years]) were enrolled at home, and 67% (1694/2532) completed clinic follow-up (Figure 1). All urine samples were tested for S haematobium ova by microscopy, and 99.4% (2517/2532) were tested for CAA. Visual FGS was available for 99.8% (1691/1694) of participants. HR-HPV DNA testing was performed on 98.3% (2488/2532) of participants, and 96.5% (2401/2488) gave valid HR-HPV results. Molecular FGS diagnosis was available for all participants (Figure 1). Data for both HR-HPV and molecular FGS status were available for 94.8% (2401/2532) of participants, and for HR-HPV and visual FGS in 96.7% (1639/1694) of clinic attendees. Flow diagram showing participant recruitment at baseline for the Zipime-Weka-Schista study and screening of molecular female genital schistosomiasis (FGS), visual FGS, and high-risk human papillomavirus (HR-HPV). 2,701 women were approached to take part of the study at home, 2,532 were enrolled in the study and 1,694 completed clinic follow-up. All enrolled women were screened for molecular FGS and HR-HPV; 1,693 were screened fro visual FGS. Among the study population, 165 women tested positive for molecular FGS, 595 for visual FGS and 690 for HR-HPV. Participant Characteristics Of 2532 women, 165 (6.5%) tested positive for molecular FGS (median Ct value, 35.1 [IQR, 7.4–31.6]) (Table 1). Prevalence of visual FGS was 35.2% (595/1691). Among women with molecular FGS, 39.0% (46/165) were visual FGS positive. Of the 595 women with visual FGS, 46 (7.7%) were also diagnosed with molecular FGS. Prevalence of egg-patent S haematobium infection was 5.2% (132/2532) (mean intensity: 4.8 eggs/10 mL of urine; standard deviation [SD], 5.5) and Schistosoma CAA was 15.4% (388/2517) (median CAA concentration, 4.6 pg/mL [IQR, 1.1–31.0 pg/mL]). HIV prevalence was 17.5% (443/2532), and 91.6% (406/443) self-reported antiretroviral therapy (ART) use. Trichomonas vaginalis prevalence was 10.3% (246/2389). Table 1.Prevalence of Any High-Risk Human Papillomavirus Stratified by Sociodemographic Characteristics and Coinfections, With Univariable Logistic Regression Estimates Across the Study Population (N = 2401)CharacteristicAllHR-HPV NegativeHR-HPV PositiveCrude OR(95% CI) P ValueTotal2532 (100)1711 (71.3)690 (28.7)…Sociodemographic characteristics Age, y 15–19330 (13.0)199 (64.0)112 (36.0)2.2 (1.3–3.5)<.001 20–25674 (26.6)412 (64.9)223 (35.1)2.1 (1.3–3.3) 26–30553 (21.8)380 (72.1)147 (27.9)1.5 (.9–2.4) 31–35341 (13.5)245 (75.9)78 (24.2)1.2 (.8–2.0) 36–40293 (11.6)223 (80.2)55 (19.8)1.0 (.6–1.6) 41–45200 (7.9)144 (75.4)47 (24.6)1.3 (.7–2.1) 46–50141 (5.6)108 (79.4)28 (20.6)Ref Marital status Single330 (13.0)559 (63.1)327 (36.9)2.0 (1.6–2.4)<.001 Married674 (26.6)1023 (77.0)306 (23.0)Ref Divorced/separated553 (21.8)92 (71.9)36 (28.1)1.3 (.9–2.0) Widowed341 (13.5)36 (63.2)21 (36.8)2.0 (1.1–3.4) Education No schooling49 (1.9)36 (78.3)10 (21.7)Ref.21 Some/completed primary school909 (35.9)620 (72.6)234 (27.4)1.4 (.7–2.8) Some/completed secondary school1344 (53.1)898 (70.2)381 (29.8)1.5 (.8–3.1) Some/completed trade school or degree229 (9.1)156 (70.6)65 (29.4)1.5 (.7–3.2) District of residence Shikoshwe1176 (46.5)818 (72.1)316 (27.9)Ref.44 Livingstone1196 (47.2)781 (70.4)328 (29.6)1.1 (.9–1.3) Chanyanya160 (6.3)112 (70.9)46 (29.1)1.1 (.7–1.5)Sexual and reproductive health behaviors and outcomes Number of sexual partners in the last 6 mo 0131 (5.2)88 (69.8)38 (30.2)Ref.49 12144 (84.7)1457 (71.7)574 (28.3)0.9 (.6–1.4) 2152 (6.0)96 (67.1)47 (32.9)1.1 (.7–1.9) ≥2105 (4.2)70 (69.3)31 (30.7)1.0 (.6–1.8) Age of sexual debut ≤15 y477 (18.9)301 (68.1)141 (31.9)Ref.03 16–20 y1768 (70.0)1205 (71.3)485 (28.7)0.9 (.7–1.1) >20 y282 (11.2)200 (75.8)64 (24.2)0.7 (.5–1.0) Time to conception of previous pregnancy 0–3 mo401 (19.2)277 (74.1)97 (25.9)Ref.4 4–6 mo95 (4.5)66 (69.5)29 (30.5)1.3 (.8–2.1) 10–12 mo1038 (49.6)722 (73.7)258 (26.3)1.0 (.8–1.3) Don’t remember31 (1.5)24 (80.0)6 (20.0)0.7 (.3–1.8) Pregnancy was unplanned529 (25.3)354 (70.0)152 (30.0)1.2 (.9–1.7) Number of pregnancies Never pregnant437 (17.3)267 (64.3)148 (35.7)1.8 (1.4–2.5)<.001 1551 (21.8)335 (64.6)184 (35.5)1.8 (1.4–2.5) 2431 (17.0)289 (71.0)118 (29.0)1.4 (1.0–1.9) 3402 (15.9)287 (74.4)99 (25.7)1.1 (.8–1.6) 4289 (11.4)227 (82.3)49 (17.8)0.7 (.5–1.1) >4422 (16.7)306 (76.9)92 (23.1)Ref Type of contraception used None10 (0.8)7 (77.8)2 (22.2)Ref.41 Barrier method (condom, diaphragm, or IUD)139 (11.4)101 (74.8)34 (25.2)1.2 (.2–5.9) Hormonal method (implant, injectable, or oral pill)999 (82.1)697 (71.7)275 (28.3)1.4 (.3–6.7) Sterilization method1 (0.1)1…Not enough data Combination (hormonal and barrier)69 (5.7)46 (68.7)21 (31.3)1.6 (.3–8.4) Number of stillbirths None1978 (94.5)1360 (72.6)513 (27.4)Ref.006 1 or more116 (5.5)351 (66.5)177 (33.5)1.3 (1.1–1.6)Coinfections HIV status Negative1970 (77.8)1330 (71.4)534 (28.7)Ref.74 Positive443 (17.5)304 (71.7)120 (28.3)1.0 (.8–1.2) Unknown119 (4.7)77 (68.1)36 (31.9)1.2 (.8–1.8) Self-reported ART use among HIV positive (n = 443) No38 (8.6)20 (54.1)17 (45.7)2.3 (1.2–2.4).02 Yes405 (91.4)284 (73.4)103 (26.6)Ref Trichomonas vaginalis status Negative2143 (89.7)1444 (71.5)575 (28.5)Ref.15 Positive246 (10.3)161 (67.1)79 (32.9)1.2 (.9–1.6) Molecular FGSa Negative2366 (93.5)1610 (71.8)633 (28.2)Ref.04 Positive165 (6.5)101 (63.9)57 (36.1)1.5 (1.0–2.0) Median Ct (IQR)35.1 (7.4–31.6)35.7 (31.3–39.0)35.1 (31.8–38.7)… Visual FGS by colposcopyb Negative1096 (64.8)729 (68.8)331 (31.2)Ref.17 Positive595 (35.2)417 (72.0)162 (28.0)0.9 (.7–1.1) Schistosoma infection by CAA Negative2129 (84.6)1437 (71.2)580 (28.8)Ref0.99 Positive388 (15.4)263 (71.3)106 (28.7)1.0 (.8–1.3) Median pg/mLc (IQR)4.6 (1.1–30.6)3.4 (1.0–26.7)10.2 (1.2–50.3)… Schistosoma haematobium by microscopy Negative2400 (94.8)1635 (71.9)639 (28.1)Ref.004 Positive132 (5.2)76 (59.8)51 (40.2)1.7 (1.2–2.5) Mean egg count (SD) per 10 mLc4.8 (5.5)4.9 (4.8)4.8 (6.7)…Data are presented as No. (%) unless otherwise indicated. Percentages (%) in the first column are based on the total number of observations (N = 2532). Percentages (%) in the second and third columns are calculated within each row total.Abbreviations: ART, antiretroviral therapy; CAA, circulating anodic antigen; CI, confidence interval; Ct, cycle threshold; FGS, female genital schistosomiasis; HIV, human immunodeficiency virus; HR-HPV, high-risk human papillomavirus; IQR, interquartile range; IUD, intrauterine device; OR, odds ratio; SD, standard deviation. aMolecular FGS refers to polymerase chain reaction (PCR) diagnosis of either home-based self-collected cervicovaginal swabs or clinic-based provider-collected cervicovaginal swabs. bVisual FGS defined as a positive if confirmed by both reviewers 1 and 2, or in case of disagreement, by reviewer 3. The associations between the single visual FGS and HR-HPV infection are presented in Supplementary Table 2. cMean egg count, CAA concentrations, and PCR Ct values are restricted to positive tests. Prevalence of Any High-Risk Human Papillomavirus Stratified by Sociodemographic Characteristics and Coinfections, With Univariable Logistic Regression Estimates Across the Study Population (N = 2401) Data are presented as No. (%) unless otherwise indicated. Percentages (%) in the first column are based on the total number of observations (N = 2532). Percentages (%) in the second and third columns are calculated within each row total. Abbreviations: ART, antiretroviral therapy; CAA, circulating anodic antigen; CI, confidence interval; Ct, cycle threshold; FGS, female genital schistosomiasis; HIV, human immunodeficiency virus; HR-HPV, high-risk human papillomavirus; IQR, interquartile range; IUD, intrauterine device; OR, odds ratio; SD, standard deviation. aMolecular FGS refers to polymerase chain reaction (PCR) diagnosis of either home-based self-collected cervicovaginal swabs or clinic-based provider-collected cervicovaginal swabs. bVisual FGS defined as a positive if confirmed by both reviewers 1 and 2, or in case of disagreement, by reviewer 3. The associations between the single visual FGS and HR-HPV infection are presented in Supplementary Table 2. cMean egg count, CAA concentrations, and PCR Ct values are restricted to positive tests. Distribution of Infection by Age Prevalence of molecular FGS was highest among adolescents aged 15–19 years (14.6%) and declined with age (χ2 < 0.001) (Figure 2, Supplementary Table 1). Visual FGS prevalence increased with age, peaking at 46–50 years (53.4%) (χ2 < 0.001; Figure 2, Supplementary Table 1). HR-HPV prevalence declined significantly with age (P < .001) (Figure 2, Table 1). Two-panel plot showing the distribution of positive diagnostic test results by age categories. Panel A shows the distribution of molecular female genital schistosomiasis (FGS) and visual FGS by age groups. Panel B shows the prevalence of any high-risk human papillomavirus (HR-HPV) infection, HPV-16/18/45, and HPV-16 only by age categories. The corresponding data are presented in Table 1 and Supplementary Table 1. **Stands for P-value < .01. Risk Factor Analysis for Prevalence of Any HR-HPV Prevalence of any HR-HPV genotypes was 28.7% (690/2401) (Table 1). Any HR-HPV prevalence was higher among women with molecular FGS compared to those without (36.1% vs 28.2%; cOR, 1.5 [95% CI, 1.0–2.0]) (Table 1). No statistically significant difference was observed by visual FGS status (visual FGS positive vs negative, 28.0% vs 31.2%; cOR, 0.9 [95% CI, .7–1.1]) (Table 1, Supplementary Table 2). Women with urinary S haematobium by microscopy had a higher prevalence of any HR-HPV compared to those without (40.2% vs 28.1; cOR, 1.7 [95% CI, 1.2–2.5]). No significant differences in HR-HPV prevalence were observed by HIV status (cOR, 1.0 [95% CI, .8–1.2]) or T vaginalis status (cOR, 1.2 [95% CI, .9–1.6]) (Table 1). After adjusting for age, marital status, and number of pregnancies, molecular FGS was weakly associated with any HR-HPV prevalence (aOR, 1.3 [95% CI, .9–1.9]) (Figure 3). Due to multicollinearity between molecular FGS and urinary S haematobium infection (r = 0.56), a separate model evaluated the association between urinary S haematobium infection by microscopy and infection with any HR-HPV (aOR, 1.7 [95% CI, 1.1–2.4]) (Supplementary Table 3). Forest plot showing adjusted odds ratios (aOR) and 95% confidence intervals for risk factors associated with prevalence of any high-risk human papillomavirus across the study population (N = 2,401). The regression model was adjusted for molecular female genital schistosomiasis status, age, marital status, and number of pregnancies. Abbreviations: aOR, adjusted odds ratio; CI, confidence interval; FGS, female genital schistosomiasis. Risk Factor Analysis for Infection With High-Risk Types HPV-16/18/45 Prevalence of infection with HPV-16/18/45 was 9.6% (231/2401) (Supplementary Table 4). In univariable analysis, higher prevalence was observed among HIV-positive versus HIV-negative women (12.5% [53/424] vs 8.9% [166/1864]; cOR, 1.5 [95% CI, 1.1–2.0]) and among women with T vaginalis (14.6% [35/240] vs 8.8% [177/2019]; cOR, 1.8 [95% CI, 1.2–2.6]) (Supplementary Table 4). HPV-16/18/45 prevalence was higher among women with molecular FGS compared to those without (15.8% [25/158] vs 9.2% [206/2243]; cOR, 1.9 [95% CI, 1.2–2.9]). No association was observed with visual FGS (cOR, 0.8 [95% CI, .6–1.2]) (Supplementary Tables 4 and 5). In adjusted analysis, molecular FGS (aOR, 1.7 [95% CI, 1.0–2.8]), HIV status (aOR, 1.7 [95% CI, 1.2–2.4]), and T vaginalis status (aOR, 1.5 [95% CI, 1.0–2.2]) were associated with increased odds of HPV-16/18/45 infection (Figure 4). Forest plot showing adjusted odds ratios (aOR) and 95% confidence intervel for risk factors associated with the prevalence of human papillomavirus type 16/18/45 across the study population (N = 2,401). The corresponding data are presented in Supplementary Table 4. The model was adjusted for molecular female genital schistosomiasis status, HIV status, Trichomonas vaginalis status, district of residence, marital status, and number of pregnancies. Abbreviations: aOR, adjusted odds ratio; CI, confidence interval; FGS, female genital schistosomiasis; HIV, human immunodeficiency virus. HPV-16 Only HPV-16 prevalence was 4.8% (114/2401) (Supplementary Table 6). HPV-16 prevalence was higher among single versus married women (6.6% [58/886] vs 3.5% [46/1329]; cOR, 2.0 [95% CI, 1.3–2.9]) (Supplementary Table 6). Women with molecular FGS had higher HPV-16 prevalence compared to those without (8.2% [13/158] vs 4.5% [101/2243]; cOR, 1.9 [95% CI, 1.0–3.5]) (Supplementary Table 6). No significant association was observed with visual FGS status (cOR, 0.8 [95% CI, .5–1.2]), urinary S haematobium status by microscopy (cOR, 1.4 [95% CI, .7–2.9]), Schistosoma status by CAA (cOR, 1.2 [95% CI, .8–2.0]), HIV status (cOR, 1.4 [95% CI, .9–2.2]), or T vaginalis status (cOR, 1.4 [95% CI, .8–2.5]) (Supplementary Tables 6 and 7). After adjusting for marital status and parity, women with molecular FGS had 1.8 higher odds of being HPV-16 positive compared to those without (aOR, 1.8 [95% CI, 1.0–3.4]) (Figure 5). Forest plot showing adjusted odds ratios (aOR) and 95% confidence intervals for factors associated with the prevalence of human papillomavirus type 16 across the study population (N = 2,401). The corresponding data are presented in Supplementary Table 6. The logistic regression model was adjusted for molecular female genital schistosomiasis status, marital status, and number of pregnancies. Abbreviations: aOR, adjusted odds ratio; CI, confidence interval; FGS, female genital schistosomiasis. DISCUSSION To our knowledge, the Zipime-Weka-Schista study is the first to investigate the association between HR-HPV and FGS, diagnosed using both visual and molecular methods, in a large cohort of women with and without HIV in Zambia [27]. We found a significant association between molecular FGS and HPV-16/18/45, the types most frequently associated with cervical precancer and cancer. No significant association was found between visual FGS and HR-HPV infection. These findings highlight the need to recognize FGS as an SRH condition and integrate FGS screening into cervical cancer control programs to reduce the dual burden of diseases in endemic settings [7]. Women with molecular FGS were almost 1.7 times more likely to test positive for HPV-16/18/45, the most oncogenic genotypes, which contribute to the majority of cervical precancer and cancer globally [12, 13]. To our knowledge, this is the first study to compare molecular FGS with HR-HPV infection from cervicovaginal self-collected swabs. FGS may influence the natural history of cervical HPV infection. HPV infects undifferentiated, proliferating basal cells of the cervicovaginal epithelium through microabrasion, often resulting from coexistence with STIs or co-factors that compromise the epithelial barrier [31]. The epithelial damage of the anogenital mucosa caused by S haematobium egg deposition in women with FGS may facilitate HPV viral entry [18]. Further, effective immune regulation is critical for HR-HPV clearance, and chronic genital inflammation associated with S haematobium egg deposition may impair local immune responses, promoting immune evasion and HR-HPV persistence [18, 31]. Although this cross-sectional analysis does not allow to distinguish between incident and persistent HR-HPV infections, the observed association between molecular FGS and HPV-16/18/45 support the hypothesis that FGS may contribute to HPV persistence. This aligns with a study in Tanzania reporting higher odds of HR-HPV persistence among women with Schistosoma infection diagnosed by CAA [26]. Although genital involvement was not assessed, it suggests that the schistosomiasis-related inflammation may promote HR-HPV persistence [26]. Longitudinal data from the ongoing Zipime-Weka-Schista study will further evaluate whether FGS affects HR-HPV persistence or clearance [27]. Women with egg-patent urinary S haematobium infection were more likely to have prevalent HR-HPV infection, compared to those without. In contrast, no significant association was observed with schistosomiasis detected by CAA. This may reflect the differences between diagnostic method [30]. CAA is a highly sensitive for active Schistosoma infection, detecting antigens released by live adult worms in the host's bloodstream [28]. However, it does not provide information on egg deposition or differentiate between species [28]. The associations observed highlight the complexity of active infection in the pathogenesis of HR-HPV in the presence of S haematobium. Visual FGS was not associated with HR-HPV prevalence. Previous studies reported mixed results, likely due to differences in outcome definitions [24, 25]. Although colposcopy is widely used to assess FGS-related morbidity, its scalability in endemic settings is limited by high cost, infrastructure requirements, and need for trained personnel [2, 6]. Importantly, the mucosal changes in visual FGS–positive women can be similar to changes from other SRH, including cervical lesions caused by HPV, resulting in limited diagnostic specificity [6, 7]. In our study, agreement between 2 expert reviewers in detecting visual FGS was low, consistent with previous research in Zambia, highlighting the need for standardized, scalable diagnostic methods [6]. Emerging computer vision technologies, powered by artificial intelligence, are being explored for visual FGS diagnosis and may be integrated with tools being validated for automated detection of cervical precancer and cancer [32–35]. HR-HPV prevalence was highest among persons aged 15–25 years, consistent with previous studies [36–39]. Prevalence of molecular FGS decreased with increasing age and peaked among adolescents aged 15–19 years, whereas more older women (aged 41–50 years) were positive for visual FGS. These findings are consistent with previous studies [3, 4, 29, 40]. This age distribution supports opportunities to integrate FGS into cervical cancer control programs [7]. As Zambia transitions from visual inspection with acetic acid to HPV DNA–based cervical screening programs, self-collection platform and laboratory infrastructures for cervical cancer screening could include molecular FGS testing, improving earlier detection [7, 20]. Younger women are more susceptible to HR-HPV infection, and have higher intensity of S haematobium infection and higher rates of Schistosoma DNA retrieval from the genital tract [3, 29, 36–40]. In contrast, older women typically show higher prevalence of visually diagnosed lesions [3, 29, 40]. This age-specific pattern suggests that molecular FGS screening could be integrated into HPV vaccination and education programs targeting younger girls (9–14 years old), while community-based integrated HPV and molecular FGS screening can be introduced for women eligible for cervical cancer screening (aged ≥25 years for women with HIV or ≥30 years for women without HIV) [19, 20]. For older women (aged >35 years), FGS screening can be integrated into existing cervical cancer clinic-based screening and/or treatment programs [19, 20]. Prevalence of any HR-HPV did not vary by HIV status, differing from previous studies [41–43]. This may reflect the high proportion of participants on ART and younger age in our cohort. ART reduces HPV persistence and precancer and cancer incidence, especially when initiated early following HIV acquisition and before significant immunosuppression [17]. Yet, these benefits have primarily been demonstrated in cohorts where women achieve sustained viral suppression through long-term ART adherence and regular cervical cancer screening. In our community-based study, ART status was self-reported, and data on CD4+ T-cell count and HIV plasma viral load were unavailable, limiting our ability to assess immune control and its associations with HPV infection. With >2500 women, this is the largest study to date to evaluate the association between HR-HPV prevalence and FGS, diagnosed using both molecular and visual methods. The integrated study design, combining home and clinic-based sampling with multiple diagnostic methods, allowed for comprehensive screening for FGS and SRH coinfections. There are some limitations worth noting. Histological examination of cervical tissues for Schistosoma eggs detection was not performed, limiting the ability to compare molecular and visual FGS diagnoses against a reference standard [2, 6, 44]. The reliability of visual FGS diagnosis was limited by low agreement between reviewers. Implementation of molecular FGS testing in routine settings is hindered by cost, technical requirements, and the need for trained personnel. Ct values may have been affected by the DNA extraction protocol, including the double-elution step, which can lower DNA concentration. Although this was applied consistently throughout the study, extraction variability may influence sensitivity and should be considered when interpreting absolute Ct values. This study accounted for HIV and T vaginalis status, but it did not address potential confounding by other STIs, which can affect cervical inflammation and epithelial integrity [45]. HIV status was self-reported for most participants, potentially introducing reporting bias. Data on CD4+ T-cell count, ART adherence and duration, and HIV plasma viral load were not collected, potentially introducing confounding. Further, the cross-sectional design does not distinguish between incident and persistent HR-HPV infections, limiting causal inferences. Longitudinal data from the ongoing Zipime-Weka-Schista study will address some of these limitations [27]. This study provides new evidence on the intersection of FGS, HR-HPV, and SRH among women of reproductive age, highlighting a significant association between molecular FGS and the most oncogenic HPV genotypes (HPV-16/18/45). In line with the Sustainable Development Goals and the WHO targets to eliminate cervical cancer and schistosomiasis, our findings support integrated strategies using highly specific, field-deployable, and cost-effective diagnostic methods. Supplementary Material